m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01703)
Name
Bupropion
Synonyms
Amfebutamon; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; (+-)-Bupropion; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; 34841-39-9; 34911-55-2; AMFEBUTAMONE HCl; Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; Amfebutamon; Amfebutamona; Amfebutamona [INN-Spanish]; Amfebutamone; Amfebutamonum; Amfebutamonum [INN-Latin]; BRN 2101062; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Bupropion Hcl; Bupropion SR; Bupropion [INN:BAN]; Bupropion hydrocloride; CHEBI:3219; CHEMBL894; Elont; Elontril; SNPPWIUOZRMYNY-UHFFFAOYSA-N; Wellbatrin; Zyban; alpha-(tert-butylamino)-m-chloropropiophenone; amfebutamonum; bupropion
    Click to Show/Hide
Status
Approved
Structure
Formula
C13H18ClNO
InChI
1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
InChIKey
SNPPWIUOZRMYNY-UHFFFAOYSA-N
PubChem CID
444
VARIDT Drug ID
DR00836
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Bupropion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bupropion through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Bupropion. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Bupropion through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Bupropion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bupropion through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [4]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6. doi: 10.1016/j.bcp.2010.06.025. Epub 2010 Jun 23.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.